Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV.
Giulia MorsicaLaura GalliEmanuela MessinaAntonella CastagnaSabrina BagaglioStefania SalpietroDella Torre LivianaCaterina Uberti-FoppaHamid HassonPublished in: PloS one (2022)
Our findings underline the importance for close monitoring HIV-VL in selected patients. Whether this phenomenon is triggered by the rapid clearance of HCV remains to be established.
Keyphrases
- antiretroviral therapy
- hepatitis c virus
- hiv infected patients
- human immunodeficiency virus
- hiv infected
- hiv positive
- end stage renal disease
- hiv aids
- ejection fraction
- newly diagnosed
- chronic kidney disease
- sars cov
- prognostic factors
- peritoneal dialysis
- men who have sex with men
- south africa
- patient reported outcomes
- patient reported
- combination therapy
- quantum dots